Acceso a Miembros

 Agradecemos a:





Bienvenidos, en esta sección podrá tener información de primera mano sobre los protocolos que estan reclutando pacientes.

(en inglés, seleccionar este botón para traducir, parte superior derecha Resultado de imagen para traductor de google)

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments. (SOLO3)

Leer más...

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by AstraZeneca
Myriad Genetic Laboratories, Inc.
Information provided by (Responsible Party):










Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.

Ages Eligible for Study:   18 Years to 96 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity Drug: OLAPARIB
Drug: Single agent chemotherapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.


Leer más...